HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Krohn, K. A. Articles by Mason, R. P. Search for Related Content PubMed PubMed Citation Articles by Krohn, K. A. Articles by Mason, R. P.

Molecular Imaging of Hypoxia

¹ Department of Radiology, University of Washington, Seattle, Washington; and ² Department of Radiology, University of Texas, Southwestern Medical Center, Dallas, Texas

Correspondence: For correspondence or reprints contact: Kenneth A. Krohn, Department of Radiology, University of Washington, 1959 NE Pacific St., Room NW041, Box 356004, Seattle, WA 98195-6004. E-mail: kkrohn{at}u.washington.edu

Hypoxia, a condition of insufficient O₂ to support metabolism, occurs when the vascular supply is interrupted, as in stroke or myocardial infarction, or when a tumor outgrows its vascular supply. When otherwise healthy tissues lose their O₂ supply acutely, the cells usually die, whereas when cells gradually become hypoxic, they adapt by up-regulating the production of numerous proteins that promote their survival. These proteins slow the rate of growth, switch the mitochondria to glycolysis, stimulate growth of new vasculature, inhibit apoptosis, and promote metastatic spread. The consequence of these changes is that patients with hypoxic tumors invariably experience poor outcome to treatment. This has led the molecular imaging community to develop assays for hypoxia in patients, including regional measurements from O₂ electrodes placed under CT guidance, several nuclear medicine approaches with imaging agents that accumulate with an inverse relationship to O₂, MRI methods that measure either oxygenation directly or lactate production as a consequence of hypoxia, and optical methods with NIR and bioluminescence. The advantages and disadvantages of these approaches are reviewed, along with the individual strategies for validating different imaging methods. Ultimately the proof of value is in the clinical performance to predict outcome, select an appropriate cohort of patients to benefit from a hypoxia-directed treatment, or plan radiation fields that result in better local control. Hypoxia imaging in support of molecular medicine has become an important success story over the last decade and provides a model and some important lessons for development of new molecular imaging probes or techniques.

Key Words: hypoxia • ¹⁸F-FMISO • Cu-ATSM • biomarkers • bioluminescence • MRI

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.